Literature DB >> 33658973

Case Report and Review of the Literature: Fatal Reversible Cerebral Vasoconstriction Syndrome.

Gautier Breville1, Amelie Bailly2, Loraine Fisch1,3, Zsolt Kulcsar4, Deborah Pugin2, Emmanuel Carrera1.   

Abstract

Background: A fatal outcome occurs in 2% of patients with Reversible Cerebral Vasoconstriction Syndrome (RCVS). Due to its rarity, guidelines for the management of the most severe forms of RCVS are lacking. Case presentation: Here, we describe the case of a 55 year-old woman who died from complications of RCVS and reviewed patients with fatal outcome reported in the literature. In our patient, the first episode of neurological deterioration was preceded by an increase of cerebral blood flow velocities assessed with transcranial Doppler. A fatal evolution could not be prevented despite therapeutic escalation consisting of multiple non-invasive and invasive treatments including cervical sympathetic bloc and continuous arterial infusion of nimodipine at the site of severe vasoconstriction.
Conclusion: This case and the review of literature illustrate the challenges in the management of patients with severe RCVS. We describe here how monitoring of cerebral blood flow might help anticipate clinical worsening at the beginning of the disease and propose novel invasive and non-invasive therapeutic strategies based on monitoring of neurophysiological parameters.
Copyright © 2021 Breville, Bailly, Fisch, Kulcsar, Pugin and Carrera.

Entities:  

Keywords:  angioplasty; calcium channel blocker; case report; literature review of fatal outcome; reversible cerebral vasoconstriction syndrome; stroke

Year:  2021        PMID: 33658973      PMCID: PMC7917125          DOI: 10.3389/fneur.2021.589062

Source DB:  PubMed          Journal:  Front Neurol        ISSN: 1664-2295            Impact factor:   4.003


  1 in total

1.  Fulminant Reversible Cerebral Vasoconstriction Syndrome in Breakthrough COVID 19 Infection.

Authors:  Somdattaa Ray; Vikram V Kamath; Arjun Raju P; Rajesh Kn; Shalini N
Journal:  J Stroke Cerebrovasc Dis       Date:  2021-11-26       Impact factor: 2.136

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.